|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6831 USD | +1.94% |
|
-14.24% | -51.55% |
| Mar. 27 | Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating | MT |
| Mar. 26 | Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024 |
Lucid Diagnostics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 2.43 million compared to USD 0.377 million a year ago. Net loss was USD 52.67 million compared to USD 56.17 million a year ago.
Basic loss per share from continuing operations was USD 1.26 compared to USD 1.55 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -51.55% | 32.96M | |
| +73.17% | 12.38B | |
| -18.74% | 7.92B | |
| +16.15% | 7.2B | |
| +4.81% | 5.84B | |
| +5.99% | 5.01B | |
| +27.07% | 4.53B | |
| -21.67% | 3.88B | |
| -40.82% | 2.23B | |
| +1.49% | 2.02B |
LUCID DIAGNOSTICS INC. 
